-
2024-519655-28-00
5
2026-04-23
Premenopausal patients with high-risk HR-positive/HER2-negative breast
-
2025-522279-27-00
5
2026-04-02
Newly Diagnosed AML with an NPM1 mutation
-
2025-521314-25-00
5
2026-03-19
NPM1-m and KMT2A-r Acute Myeloid Leukemia
-
2024-519579-24-00
5
2026-02-26
Classic Congenital Adrenal Hyperplasia
-
2024-515332-80-00
5
2026-02-23
Bacterial vaginosis
-
2025-521558-40-00
5
2026-02-12
Pulmonary Hypertension Associated with Interstitial Lung Disease
-
2024-510778-26-00
4
2025-12-19
Metastatic Non-Small-Cell Lung Cancer
-
2025-521672-60-00
7
2025-12-19
Metastatic or locally advanced SST2-positive neuroendocrine neoplasms
-
2025-520982-39-00
5
2025-12-09
Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-
-
2024-518006-40-00
5
2025-11-13
Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD)
-
2025-521775-31-00
5
2025-11-12
Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
-
2025-521055-23-00
10
2025-10-07
Chronic Idiopathic thrombocytopenic purpura
-
2024-516525-31-01
5
2025-07-14
Primary Biliary Cholangitis
-
2024-513965-38-01
5
2025-06-16
Sjögren's Disease
-
2023-509370-39-00
5
2025-06-03
connective tissue diseases
-
2024-512659-19-00
10
2025-03-31
Advanced Melanoma
-
2024-515445-42-00
5
2025-03-24
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
-
2023-507097-41-01
5
2025-03-20
Patients with limited-stage small cell lung cancer (LS-SCLC)
without
-
2024-513018-36-00
5
2025-03-06
Lung Diseases, Interstitial
-
2024-512536-29-00
4
2025-02-28
Amyotrophic Lateral Sclerosis (ALS)
-
2023-507853-13-00
4
2025-02-25
Ulcerative Colitis
-
2024-513317-12-00
5
2025-02-05
Pancreatic cancer
-
2024-512926-27-00
5
2024-12-12
patients with estrogen receptor-positive/human epidermal growth factor
-
2024-511404-17-00
5
2024-10-07
Unresectable or metastatic NRAS mutant cutaneous melanoma